AQUA® Technology Uses Extend Beyond Protein: Effective measurement of .
MDx/CDx Focus: NanoString Kicks off Second PAM50 Validation Study; MDxHealth ... - GenomeWeb
MDx/CDx Focus: NanoString Kicks off Second PAM50 Validation Study; MDxHealth .
NanoString Initiates Second Clinical Validation Study for Breast Cancer Assay - MarketWatch (press release)
NanoString Initiates Second Clinical Validation Study for Breast Cancer AssayMarketWatch (press release)The ABCSG8 study, initiated in 1996, demonstrated that compared to treatment with tamoxifen alone, sequential adjuvant treatment with tamoxifen followed by anastrozole in postmenopausal women with hormone receptor-positive early-stage breast cancer .
The Downside of Chemoprevention for Breast Cancer - Medscape
The Downside of Chemoprevention for Breast CancerMedscapeIn this study, both tamoxifen and raloxifene were shown to be effective in reducing breast cancer risk.